207 related articles for article (PubMed ID: 27738784)
1. Venous thromboembolism in chronic kidney disease: epidemiology, the role of proteinuria, CKD severity and therapeutics.
Dobrowolski C; Clark EG; Sood MM
J Thromb Thrombolysis; 2017 Feb; 43(2):241-247. PubMed ID: 27738784
[TBL] [Abstract][Full Text] [Related]
2. [Venous thromboembolic complications in patients with chronic kidney disease: prevalence and features of drug treatment].
Dzhioeva ON; Orlova AA; Rogozhkina EA; Drapkina OM
Ter Arkh; 2022 Jan; 94(1):129-134. PubMed ID: 36286928
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
Fanola CL
Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
[TBL] [Abstract][Full Text] [Related]
4. Renal function and venous thromboembolic diseases.
Janus N; Mahé I; Launay-Vacher V; Laroche JP; Deray G
J Mal Vasc; 2016 Dec; 41(6):389-395. PubMed ID: 28029509
[TBL] [Abstract][Full Text] [Related]
5. Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease.
Harel Z; Sood MM; Perl J
Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):183-92. PubMed ID: 25636144
[TBL] [Abstract][Full Text] [Related]
6. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts.
Mahmoodi BK; Gansevoort RT; Næss IA; Lutsey PL; Brækkan SK; Veeger NJ; Brodin EE; Meijer K; Sang Y; Matsushita K; Hallan SI; Hammerstrøm J; Cannegieter SC; Astor BC; Coresh J; Folsom AR; Hansen JB; Cushman M
Circulation; 2012 Oct; 126(16):1964-71. PubMed ID: 22977129
[TBL] [Abstract][Full Text] [Related]
7. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
Bauersachs R
Thromb Res; 2016 Aug; 144():12-20. PubMed ID: 27263046
[TBL] [Abstract][Full Text] [Related]
8. UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey.
Parker K; Choudhuri S; Lewis P; Thachil J; Mitra S
BMC Nephrol; 2023 Jan; 24(1):9. PubMed ID: 36635661
[TBL] [Abstract][Full Text] [Related]
9. Chronic kidney disease is associated with increased risk of venous thromboembolism recurrence.
Rattazzi M; Villalta S; De Lucchi L; Sponchiado A; Galliazzo S; Faggin E; Pagliara V; Zilli C; Callegari E; Caberlotto L; Puato M; Pauletto P
Thromb Res; 2017 Dec; 160():32-37. PubMed ID: 29091810
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism, factor VIII and chronic kidney disease.
Cheung KL; Bouchard BA; Cushman M
Thromb Res; 2018 Oct; 170():10-19. PubMed ID: 30081388
[TBL] [Abstract][Full Text] [Related]
11. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality.
Königsbrügge O; Lötsch F; Zielinski C; Pabinger I; Ay C
Thromb Res; 2014 Jul; 134(1):44-9. PubMed ID: 24792954
[TBL] [Abstract][Full Text] [Related]
12. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
13. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants.
Wharin C; Tagalakis V
Blood Rev; 2014 Jan; 28(1):1-8. PubMed ID: 24360911
[TBL] [Abstract][Full Text] [Related]
14. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
Poli D; Antonucci E; Zanazzi M; Grifoni E; Testa S; Ageno W; Palareti G
Thromb Haemost; 2012 Jun; 107(6):1100-6. PubMed ID: 22535516
[TBL] [Abstract][Full Text] [Related]
15. Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism.
Piovella F; Iosub DI
Thromb Res; 2017 Apr; 152():87-92. PubMed ID: 28017344
[TBL] [Abstract][Full Text] [Related]
16. Review: In CKD, novel oral anticoagulants do not differ from vitamin K antagonists for efficacy or bleeding.
Winkelmayer WC
Ann Intern Med; 2014 Sep; 161(6):JC10. PubMed ID: 25222410
[No Abstract] [Full Text] [Related]
17. Guidance for the prevention and treatment of cancer-associated venous thromboembolism.
Khorana AA; Carrier M; Garcia DA; Lee AY
J Thromb Thrombolysis; 2016 Jan; 41(1):81-91. PubMed ID: 26780740
[TBL] [Abstract][Full Text] [Related]
18. Treatment of venous thromboembolism in cancer patients.
Petralia GA; Kakkar AK
Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism management: where do novel anticoagulants fit?
Spyropoulos AC; Turpie AG
Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation strategies for venous thromboembolism: moving towards a personalised approach.
Black SA; Cohen AT
Thromb Haemost; 2015 Oct; 114(4):660-9. PubMed ID: 26084864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
